
SMTI Stock Forecast & Price Target
SMTI Analyst Ratings
Bulls say
Sanara MedTech Inc. has demonstrated strong sales growth in its surgical soft tissue repair products, with a 24% year-over-year increase, resulting in revenues of $23.4 million, signaling heightened demand for its key offerings such as CellerateRX Surgical and BIASURGE. The company’s preliminary financial results indicate a positive trajectory, with expected revenue growth of 13-17% for 2026 and profitability achieved in the third quarter of 2025. Furthermore, strategic partnerships, including a new contract with Vizient that enhances market access and operational efficiency, position Sanara MedTech favorably for sustainable revenue growth and improved profitability in the future.
Bears say
Sanara MedTech reported net revenue of $26.3 million, reflecting a year-over-year growth of 21.5%, which was slightly below expectations. The company faces several risks that could adversely impact future performance, including lower-than-projected revenue growth, challenges in acquiring new customers, delays in product launches, and the potential for shareholder dilution. Additionally, a revision of the company's EV/Revenue multiple from 4.3x to 3.0x indicates a diminished outlook following the exclusion of telehealth from its business model.
This aggregate rating is based on analysts' research of Sanara MedTech Inc. and is not a guaranteed prediction by Public.com or investment advice.
SMTI Analyst Forecast & Price Prediction
Start investing in SMTI
Order type
Buy in
Order amount
Est. shares
0 shares